Compare Crocs, Inc. (CROX) vs TG Therapeutics Inc (TGTX) Price & Performance

Crocs (CROX) trades at $114.98, down 0.19% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The company reported strong Q2 2026 EPS of $4.55, beating expectations by $0.20, but faces challenges with a negative net income of -$81.20M for 2025. Valuation metrics remain attractive with a P/E of 10.37 and P/S of 1.48, while analyst consensus leans bullish with a $136.78 price target representing 19% upside potential.

CROX presents a mixed investment case with compelling valuation and strong brand positioning offset by recent profitability concerns. The key opportunity lies in the company's product innovation and HEYDUDE brand reset, while risks include consumer spending volatility and execution challenges. With 51% of analysts maintaining buy ratings, the stock offers potential upside if management can restore consistent profitability growth.

TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.

The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.